Institute of Biomedical Research Corp. (MRES) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MRES, $ (piyasa değeri 0) fiyatla Healthcare işi olan Institute of Biomedical Research Corp.'i temsil ediyor. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 42/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 16 Mar 2026Institute of Biomedical Research Corp. (MRES) Sağlık ve Boru Hattı Genel Bakışı
Institute of Biomedical Research Corp., based in Montenegro, offers biomedical research, analytical services, and product development. The company focuses on regulatory compliance, environmental surveillance, and creating innovative healthcare solutions. With a global reach, including a Canadian office, it serves the biotechnology sector through diverse research and product offerings.
Yatırım Tezi
Institute of Biomedical Research Corp. operates in a niche segment of the biotechnology industry, focusing on biomedical research, analytical services, and specialized product development. With a market capitalization of $0.01 billion and a negative P/E ratio of -26.31, the company's financial performance reflects challenges in achieving profitability, indicated by a profit margin of -588.7%. However, a gross margin of 38.4% suggests potential in its core operations. Growth catalysts include expanding its regulatory and environmental service offerings, as well as commercializing its range of biomedical products. Key risks involve achieving sustainable profitability and navigating regulatory hurdles in international markets.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market capitalization of $0.01 billion reflects its small size within the biotechnology sector.
- Negative P/E ratio of -26.31 indicates the company is currently not profitable.
- Profit margin of -588.7% highlights significant challenges in achieving profitability.
- Gross margin of 38.4% suggests potential in its core operations despite overall losses.
- Beta of 0.04 indicates low volatility relative to the market.
Rakipler & Benzerleri
Güçlü Yönler
- Diverse range of biomedical research and analytical services.
- Development and commercialization of specialized biomedical products.
- Expertise in regulatory compliance and environmental analysis.
- Established presence in Montenegro with international reach.
Zayıflıklar
- Low profitability and negative profit margins.
- Limited market capitalization and financial resources.
- Dependence on niche markets and specialized applications.
- OTC market listing may limit investor access and liquidity.
Katalizörler
- Ongoing: Expansion of regulatory and environmental service offerings.
- Upcoming: Commercialization of new biomedical products in international markets.
- Ongoing: Development of new diagnostic methods and experimental treatments.
- Upcoming: Strategic partnerships with research institutions and healthcare providers.
Riskler
- Ongoing: Low profitability and negative profit margins.
- Potential: Limited market capitalization and financial resources.
- Ongoing: Dependence on niche markets and specialized applications.
- Potential: OTC market listing may limit investor access and liquidity.
- Potential: Intense competition in the biotechnology sector.
Büyüme Fırsatları
- Expanding Regulatory and Environmental Services: Institute of Biomedical Research Corp. can capitalize on the growing demand for regulatory compliance and environmental services. By offering specialized services in regulatory certifications and environmental analysis, the company can attract clients seeking to navigate complex regulatory landscapes. The market for environmental services is projected to reach $1.2 trillion by 2027, presenting a significant growth opportunity.
- Commercializing Biomedical Products: The company has the potential to drive revenue growth by commercializing its range of biomedical products, including microbicidal agents, disinfectant products, and healthcare devices. Focusing on niche markets and specialized applications can help the company differentiate its products and capture market share. The global market for medical devices is expected to reach $600 billion by 2025.
- Developing New Diagnostic Methods: Investing in the development of new diagnostic methods and experimental medical treatments can position the company as an innovator in the biotechnology sector. By focusing on unmet medical needs and emerging technologies, the company can attract research funding and partnerships. The market for diagnostic testing is projected to reach $115 billion by 2028.
- Geographic Expansion: Expanding its geographic reach beyond Montenegro and Canada can open up new markets and revenue streams. Targeting regions with growing healthcare sectors and unmet medical needs can help the company diversify its operations and reduce its reliance on domestic markets. Emerging markets in Asia and Latin America offer significant growth potential.
- Strategic Partnerships: Forming strategic partnerships with other companies in the biotechnology sector can provide access to new technologies, markets, and resources. Collaborating with research institutions, pharmaceutical companies, and healthcare providers can accelerate product development and commercialization. Strategic alliances can also help the company expand its capabilities and enhance its competitive position.
Fırsatlar
- Expanding regulatory and environmental service offerings.
- Commercializing biomedical products in new markets.
- Developing new diagnostic methods and experimental treatments.
- Forming strategic partnerships with other companies and institutions.
Tehditler
- Intense competition in the biotechnology sector.
- Stringent regulatory requirements and compliance costs.
- Economic downturns and market volatility.
- Technological advancements and disruptive innovations.
Rekabet Avantajları
- Specialized Expertise: Deep expertise in biomedical research, regulatory compliance, and environmental analysis.
- Proprietary Technologies: Development and commercialization of unique biomedical products and technologies.
- Regulatory Certifications: Ability to provide regulatory certifications for new biomedical products.
- Established Presence: Long-standing presence in Montenegro with a growing international footprint.
MRES Hakkında
Founded in 2010, Institute of Biomedical Research Corp. is a biotechnology company based in Podgorica, Montenegro, with a representative office in Montreal, Canada. The company provides a range of biomedical research and analytical services both domestically and internationally. Its core activities encompass regulatory control of industrial activities and products, scientific surveillance of the living environment, and research and development of biomedical products and technologies. The company also focuses on regulatory evaluation and certification of biomedical products, fundamental scientific research, and the development of new diagnostic methods and experimental medical treatments. Institute of Biomedical Research Corp. researches and develops new biomedical and food products, offering graduate research programs in biomedical and environmental fields. The company provides a variety of healthcare devices, including analog NMS, digital muscle stimulators, and ultrasound devices. It also develops and commercializes microbicidal agents, disinfectant products, and various specialized products like bandages for burns, insecticides, and microbicidal towels. Further, the company offers services such as quality control, regulatory consulting, healthcare solutions, environmental analysis, building decontamination, and environmental protection and management. It also provides regulatory certifications for new biomedical products. The company's innovations include Purilair, a device for sterilizing compressed air in medical instruments, colloidal silver products, electro medical devices, and BioStim INF, used for edema reduction and pain relief.
Ne Yaparlar
- Provides regulatory control of industrial activities and products.
- Conducts scientific surveillance of the living environment.
- Engages in research and development of biomedical products and technologies.
- Offers regulatory evaluation and certification of biomedical products.
- Conducts fundamental scientific research.
- Develops new diagnostic methods and experimental medical treatments.
- Researches and develops new biomedical and food products.
- Provides programs for graduate research studies in biomedical and environmental fields.
İş Modeli
- Provides biomedical research and analytical services to various industries.
- Develops and commercializes biomedical products and technologies.
- Offers regulatory evaluation and certification services for biomedical products.
- Generates revenue through the sale of healthcare devices and specialized products.
Sektör Bağlamı
Institute of Biomedical Research Corp. operates within the global biotechnology industry, which is characterized by rapid innovation, stringent regulatory requirements, and intense competition. The company's focus on biomedical research, analytical services, and specialized product development positions it within a niche segment of the market. Key trends in the industry include the increasing demand for personalized medicine, the growing importance of regulatory compliance, and the rise of environmental concerns. Competitors include companies like BBIXF, CAAOF, CHOOF, CLYYF, and ELVAF, which operate in similar areas of biomedical research and product development.
Kilit Müşteriler
- Industrial companies requiring regulatory control and compliance.
- Healthcare providers seeking advanced diagnostic methods and treatments.
- Research institutions and universities involved in biomedical research.
- Government agencies responsible for environmental surveillance and protection.
Finansallar
Grafik & Bilgi
Institute of Biomedical Research Corp. (MRES) hisse senedi fiyatı: Price data unavailable
Son Haberler
-
Stocks That Hit 52-Week Lows On Tuesday
· 8 Eki 2019
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
MRES için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
MRES için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, MRES'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Yönetim: Drasko D. Pekovic
CEO
Drasko D. Pekovic serves as the CEO of Institute of Biomedical Research Corp. His background includes extensive experience in biomedical research and development, with a focus on regulatory compliance and environmental analysis. He has been instrumental in guiding the company's strategic direction and expanding its international presence. Dr. Pekovic holds advanced degrees in biomedical sciences and has published numerous research papers in peer-reviewed journals.
Sicil: Under Dr. Pekovic's leadership, Institute of Biomedical Research Corp. has expanded its range of biomedical research and analytical services, as well as developed and commercialized several specialized biomedical products. He has also overseen the company's efforts to obtain regulatory certifications and expand its geographic reach. Key milestones include establishing a representative office in Montreal, Canada, and securing partnerships with research institutions.
MRES OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of the OTC market, indicating that Institute of Biomedical Research Corp. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the potential for limited information and liquidity.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited liquidity and trading volume.
- Lack of regulatory oversight and financial disclosure.
- Potential for price manipulation and fraud.
- Higher risk of delisting or going out of business.
- Limited access to capital and financing options.
- Verify the company's financial statements and disclosures.
- Research the background and experience of the management team.
- Assess the company's business model and competitive position.
- Evaluate the company's regulatory compliance and legal risks.
- Check for any red flags or warning signs in the company's history.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Established presence in Montenegro with international reach.
- Development and commercialization of specialized biomedical products.
- Expertise in regulatory compliance and environmental analysis.
- CEO with extensive experience in biomedical research and development.
Yatırımcılar Institute of Biomedical Research Corp. (MRES) Hakkında Ne Soruyor
MRES için değerlendirilmesi gereken temel faktörler nelerdir?
Institute of Biomedical Research Corp. (MRES) şu anda yapay zeka skoru 42/100, düşük puanı gösteriyor. Temel güçlü yan: Diverse range of biomedical research and analytical services.. İzlenmesi gereken birincil risk: Ongoing: Low profitability and negative profit margins.. Bu bir finansal tavsiye değildir.
MRES MoonshotScore'u nedir?
MRES şu anda MoonshotScore'da 42/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
MRES verileri ne sıklıkla güncellenir?
MRES fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler MRES hakkında ne diyor?
MRES için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
MRES'a yatırım yapmanın riskleri nelerdir?
MRES için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Ongoing: Low profitability and negative profit margins.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
MRES'ın P/E oranı nedir?
MRES için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için MRES'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
MRES aşırı değerli mi, yoksa düşük değerli mi?
Institute of Biomedical Research Corp. (MRES)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
MRES'ın temettü verimi nedir?
Institute of Biomedical Research Corp. (MRES) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Limited financial information available for Institute of Biomedical Research Corp.
- OTC market listing increases investment risk.